Bruton’s Tyrosine Kinase Inhibitor Rilzabrutinib Wins FDA Approval as First Treatment for Immune Thrombocytopenia Purpura (ITP)

.

FDA Approves First-in-Class treatment for Immune Thrombocytopenia

Yesterday, the Food and Drug Administration (FDA) approved rilzabrutinib (Wayrilz; Sanofi) as a first-in-class treatment for immune thrombocytopenia (ITP), a rare autoimmune disorder. ITP is characterized by platelet counts below 100,000/μL, driven by both increased platelet destruction and decreased production. In addition to bruising and bleeding, which may lead to life-threatening events like intracranial hemorrhage, patients are at risk for arterial or venous thrombosis. Many also experience symptoms that contribute to a reduced quality of life, like unexplained fatigue, cognitive impairment, and anxiety or depression.

Rilzabrutinib is an oral, reversible covalent Bruton tyrosine kinase (BTK) inhibitor. BTK is expressed in B cells, macrophages, and other immune cells and plays a central role in the inflammatory pathways involved in ITP. By selectively inhibiting BTK, rilzabrutinib may reduce disease activity while minimizing the risk of off-target adverse effects.

“With its differentiated mechanism of action,Wayrilz has the potential to become a treatment of choice for immune thrombocytopenia patients who have not responded to a prior therapy,” Brian Foard,executive vice president and head of specialty care at Sanofi,said in a statement.

The FDA’s decision was based on results from the randomized, multicenter phase 3 LUNA 3 study (NCT04562766), which evaluated the efficacy and safety of rilzabrutinib vs placebo in adults and adolescents with persistent or chronic ITP. Participants received 400 mg of oral rilzabrutinib twice daily or placebo during a 12- to 24-week double-blind period, followed by a 28-week open-label phase and a 4-week safety follow-up or long-term extension period.

The trial’s primary endpoint was durable platelet response, defined as achieving platelet counts of at least 50,000/μL for at least 8 of the 12 weeks in the double-blind period without rescue therapy. Secondary endpoints included time to response, duration of response, and use of rescue therapy.

What specific autoimmune pathways are disrupted by rilzabrutinib’s inhibition of Bruton’s Tyrosine Kinase (BTK) in the context of ITP?

Rilzabrutinib: FDA Breakthrough for Immune Thrombocytopenia (ITP)

Understanding Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia Purpura (ITP),formerly known as idiopathic thrombocytopenic purpura,is an autoimmune disorder where the immune system mistakenly attacks and destroys platelets. Platelets are crucial for blood clotting,and a low platelet count (thrombocytopenia) leads to an increased risk of bleeding. Symptoms range from mild bruising to severe, life-threatening hemorrhage. Current treatments for ITP frequently enough have limitations, including side effects and inconsistent efficacy. these include corticosteroids, intravenous immunoglobulin (IVIG), and splenectomy.

Key Symptoms of ITP

Easy bruising (purpura)

Fatigue

Prolonged bleeding from cuts

Nosebleeds

Bleeding gums

Heavy menstrual periods

Tiny red or purple spots on the skin (petechiae)

Rilzabrutinib: A Novel BTK Inhibitor

Rilzabrutinib, developed by Rigel Pharmaceuticals, is a selective, covalent Bruton’s Tyrosine Kinase (BTK) inhibitor.BTK plays a critical role in the signaling pathways of B cells, which are key players in the autoimmune response driving ITP. By inhibiting BTK, rilzabrutinib aims to reduce the destruction of platelets. This marks a critically important advancement in ITP treatment options.

How Rilzabrutinib Works: Targeting the Autoimmune Cascade

Rilzabrutinib’s mechanism of action differs from existing ITP therapies. rather of broadly suppressing the immune system (like corticosteroids), it specifically targets the BTK pathway within B cells. This targeted approach potentially minimizes off-target effects and improves the risk-benefit profile. The drug effectively disrupts the signaling that leads to platelet autoantibody production.

FDA Approval and Clinical Trial Data

On August 30, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to rilzabrutinib for adult patients with chronic ITP who have had an insufficient response to prior treatment. This approval is based on data from the pivotal Phase 3 RAINIER study.

RAINIER Study Highlights: Efficacy and Safety

The RAINIER study demonstrated that rilzabrutinib considerably increased platelet counts in patients with chronic ITP. Key findings include:

1. Rapid Platelet Count Increase: A significant proportion of patients achieved platelet counts ≥30 x 10⁹/L within weeks of starting rilzabrutinib.
2. Sustained Response: Many patients maintained stable platelet counts over the duration of the study.
3. Reduced Bleeding Risk: Improvements in platelet counts correlated with a reduction in bleeding events.
4. Safety Profile: The most common adverse events were upper respiratory tract infection, nasopharyngitis, and headache. Serious adverse events were relatively uncommon.

Benefits of Rilzabrutinib for ITP Patients

Rilzabrutinib offers several potential advantages over existing ITP treatments:

Targeted Therapy: Specifically addresses the underlying autoimmune mechanism.

Oral Administration: Convenient oral formulation improves patient adherence.

Potential for Long-Term Control: Demonstrated sustained platelet count increases in clinical trials.

Novel Mechanism: Provides an choice for patients who have failed other therapies.

Improved Quality of Life: Reduced bleeding risk and improved platelet counts can significantly enhance quality of life for ITP sufferers.

practical Considerations & Patient Monitoring

Patients initiating rilzabrutinib therapy require careful monitoring. Key considerations include:

Baseline Blood Counts: Complete blood counts (CBC) should be obtained before starting treatment and regularly during therapy.

Liver Function Tests: monitoring liver function is essential, as elevations in liver enzymes have been observed.

Infection Monitoring: Patients should be monitored for signs and symptoms of infection.

Drug Interactions: Rilzabrutinib can interact with other medications; a thorough medication review is crucial.

* Bleeding Risk Assessment: regular assessment of bleeding risk is necessary.

real-World Implications and future Directions

The approval of rilzabrutinib represents a paradigm shift in chronic ITP management. It provides a much-needed new option for patients who have exhausted other treatments. Further research is ongoing to explore the potential of rilzabrutinib in other autoimmune disorders where BTK plays a role. The long-term effects and optimal duration of therapy are also areas of ongoing investigation. The availability of this new ITP drug offers hope for improved outcomes and a better quality of life for individuals living with this challenging condition.